Abstract
Background SARS-CoV-2 has infected millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the spike protein. Although studies have demonstrated anti-spike and - RBD antibodies to be protective in animal models, and convalescent plasma as a promising therapeutic option, little is known about immunoglobulin (Ig) isotypes capable of blocking infection.
Methods We studied spike- and RBD-specific Ig isotypes in convalescent and acute plasma/sera using a multiplex bead assay. We also determined virus neutralization activities in plasma, sera, and purified Ig fractions using a VSV pseudovirus assay.
Results Spike- and RBD-specific IgM, IgG1, and IgA1 were produced by all or nearly all subjects at variable levels and detected early after infection. All samples displayed neutralizing activity. Regression analyses revealed that IgM and IgG1 contributed most to neutralization, consistent with IgM and IgG fractions’ neutralization potency. IgA also exhibited neutralizing activity, but with lower potency.
Conclusion IgG, IgM and IgA are critical components of convalescent plasma used for COVID-19 treatment.
Summary of main points IgM, IgG1 and IgA1 antibodies against SARS-CoV-2 spike glycoprotein and its receptor-binding domain are present in convalescent COVID-19 plasma. Like IgG, IgM and IgA contribute to virus neutralization, providing the basis for optimal selection of convalescent plasma for COVID-19 treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Microbiology Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health System Translational Science Hub, National Institutes of Health [grant U54TR001433]; the Personalized Virology Initiative supported by institutional funds and philanthropic donations (to V.S.); the Department of Medicine of the Icahn School of Medicine at Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance [contract HHSN272201400008C] (to F.K., V.S.); the Department of Veterans Affairs [Merit Review Grant I01BX003860] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institute of Allergy and Infectious Diseases [grant AI139290] to C.E.H., [grant AI136916] (to V.S.), [grants R01 AI123449, R21 AI1498033] to B.L. K.Y.O. and C.S. were supported by Viral-Host Pathogenesis Training Grant T32 AI07647; K.Y.O. was additionally supported by F31 AI154739. S.I. and C-T. H. were supported by postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan), respectively.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRBs at Mount Sinai Hospital System, Icahn School of Medicine at Mount Sinai, and the James J. Peter VA Medical Center
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact: catarina.hioe{at}mssm.edu, catarina.hioe{at}va.gov
a This study was supported by the Microbiology Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health System Translational Science Hub; the Department of Medicine of the Icahn School of Medicine at Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the Department of Veterans Affairs [Merit Review Grant I01BX003860] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institutes of Health [grant AI139290] to C.E.H., [grants R01 AI123449, R21 AI1498033] to B.L, and [grant U54TR001433]. K.Y.O. and C.S. were supported by Viral-Host Pathogenesis Training Grant T32 AI07647; K.Y.O. was additionally supported by F31 AI154739. S.I. and C-T. H. were supported by postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan), respectively.
b The authors declare no competing interests.
Pre-pandemic controls included, neutralization of the D614 mutant added, statistical analyses updated, a co-author added.
Data Availability
The raw data that support the findings of this study are available from the corresponding author upon request.
